Pfizer and BioNTech Announce Positive Topline Data for mRNA …
WEBOct 26, 2023 · NEW YORK & MAINZ, GERMANY-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive topline results from a Phase 1/2 study (NCT05596734) evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age.
Newsroom - BioNTech
WEBWelcome to the BioNTech Newsroom. In this section you can find a variety of media materials and useful information to download. Media Downloads. Conference "Working Together to Promote Vaccine Equity for Africa", December 18, 2023. Africa Vaccine Equity Conference 1. Africa Vaccine Equity Conference 2. Africa Vaccine Equity Conference 3.
BioNTech Announces Positive Topline Phase 2 Results for mRNA ...
WEBJul 30, 2024 · BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma. 30 July 2024. PDF Version. Primary endpoint met in a Phase 2 trial evaluating the investigational mRNA immunotherapy BNT111 in combination with the PD-1 checkpoint inhibitor cemiplimab.
Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full …
WEBDec 11, 2020 · NEW YORK & MAINZ, Germany-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for COMIRNATY ® (COVID-19 Vaccine, mRNA) to prevent COVID-19 in individuals 16 years of age and older.
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High …
WEBSep 22, 2021 · NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced topline results from a Phase 3 randomized, controlled trial evaluating the efficacy and safety of a 30-µg booster dose of the Pfizer-BioNTech COVID-19 Vaccine in more than 10,000 individuals 16 …
Press Releases - BioNTech
WEBAug 16, 2024 · BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update. Read on. 30 July 2024. BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma. Read on. 22 July 2024. BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024.
US FDA authorizes Pfizer-BioNTech and Moderna's updated …
WEBSept 11 (Reuters) - The U.S. Food and Drug Administration (FDA) on Monday authorized updated COVID-19 vaccines from Pfizer (PFE.N) /BioNTech (22UAy.DE) and Moderna (MRNA.O) that target a recently...
BioNTech SE (BNTX) Latest Stock News & Headlines - Yahoo …
WEBGet the latest BioNTech SE (BNTX) stock news and headlines to help you in your trading and investing decisions.
FDA Approves First COVID-19 Vaccine
WEBFDA approved the first COVID-19 vaccine, which has been known as the Pfizer-BioNTech COVID-19 Vaccine, and is now marketed as Comirnaty (koe-mir’-na-tee), for the prevention of COVID-19 disease...
Jefferies upgrades BioNTech SE (BNTX) to a Buy - Markets Insider
WEB10 hours ago · Jefferies analyst Akash Tewari upgraded BioNTech SE (BNTX – Research Report) to a Buy today and set a price target of $150.00. The company’s shares closed yesterday at $123.47. Tewari covers ...